Skip to content
Trending storyDeveloping

CAR-NKT platform and 4-1BB engineering show promise against solid tumours in mouse models

1 report1 sourceupdated 3 hours ago

Start here

Synthesis

A 36-minute expert lecture on ImmuneZoom describes a mouse CAR-NKT platform in which NKT cells recognise lipid antigens in a CD1d-restricted manner, allowing off-the-shelf compatibility with lower graft-versus-host disease risk. In B16 melanoma and MC38 colon cancer models, the CAR-NKT cells outperformed CAR-T by infiltrating tumours and clearing M2 macrophages. The lecture also covers 4-1BB costimulation, which caused CAR-T death in up to 30% of some donors through TNFR-family signalling; mutating the TRAF-binding domain reduced that death and improved persistence. Dual-targeting CARs built with camelid single-domain VH antibodies performed best in dual-antigen models, are patented and licensed to a UK company. Still open: work on a soluble molecule that enhances CAR-T infiltration is under review at a GCI journal, and pancreatic cancer and glioblastoma orthotopic models are planned next.

Written by a model from the reports · updated 2 hours ago

Coverage timeline

Follow the coverage to see the different angles.

Oct 17
  1. youtube.com
    Expert lecture covers CAR-NKT platform and 4-1BB costimulation engineering for solid tumours

    A 36-minute expert lecture on ImmuneZoom describes a mouse CAR-NKT platform in which NKT cells recognise lipid antigens in a CD1d-restricted manner, offer off-the-shelf compatibility with lower GVHD risk, and outperformed CAR-T in B16 melanoma and MC38 colon cancer models by infiltrating tumours and clearing M2 macrophages. 4-1BB costimulation caused CAR-T death up to 30% in some donors via TNFR-family signalling, and mutating the TRAF-binding domain reduced death and improved persistence. Dual-targeting CARs built with camelid single-domain VH antibodies worked best in dual-antigen models, are patented and licensed to a UK company, and work on a soluble molecule enhancing CAR-T infiltration is submitted to a GCI journal, with pancreatic cancer and GBM orthotopic models planned next.

Heat trend for this story

Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –

02.557.510Oct18Oct18Oct18Oct18

The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org